Effectiveness of Janus kinase (JAK) inhibitors in biologics-naïve patients with RA: a population-based study
Main finding · Treatment changeResult — go to the resultHazard ratio 1.38 95% CI 1.25–1.53Authors' conclusion
We found JAK inhibitors had better effectiveness than TNFi biologics, with no significant difference compared with non-TNFi biologics in biologics-naïve patients.
Study context
- Population
- Biologics-naïve RA patients, Taiwan's National Health Insurance Research Database
- Participants
- 16,212 patients
- Exposure
- JAK inhibitors vs TNF inhibitor (TNFi) biologics and non-TNFi biologics in biologics-naïve RA
- JAK inhibitorsn = 2,654reference
- TNFi biologicsn = 10,080
- Non-TNFi biologicsn = 3,478
- Outcome
- Treatment change (discontinuation or switching of medications) as measure of drug retention
- Follow-up
- 2-year study period
Methodological detailspopulation-based, Taiwan's National Health Insurance Research Database
- Population-based
- Taiwan's National Health Insurance Research Database
Main finding
Treatment change
Hazard ratio
1.38
95% CI 1.25–1.53
TNFi biologicsvs JAK inhibitors
HR 1.38 (95% CI 1.25–1.53)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Treatment change, intra-class JAK inhibitors (tofacitinib vs baricitinib)
- Risk of treatment change among JAK inhibitors (tofacitinib, baricitinib) similar
Original publication
Effectiveness of JAK inhibitors in biologics-naïve patients with RA: a population-based study. Rheumatology (Oxford). Published 18 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →